Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Gentronix Awarded Grant of £147,552 by MRC and Technology Strategy Board

Published: Thursday, December 20, 2012
Last Updated: Thursday, December 20, 2012
Bookmark and Share
Company awarded grant from the Biomedical Catalyst programme for an epigenetic based screening assay feasibility study.

Gentronix Ltd., Manchester UK, has been awarded a grant of £147,552 by the Medical Research Council (MRC) and the Technology Strategy Board under the joint £180 million Biomedical Catalyst programme.

The project funded by the award will look at the feasibility of developing a screening assay for compounds that may cause cancer as a result of epigenetic mechanisms.

Before being approved for use, chemicals such as pharmaceuticals, agrochemicals and consumer products have to be tested for genetic toxicity i.e. their potential to change the DNA sequence or the number of chromosomes in a cell.

Exposure to genotoxic chemicals can lead to the development of cancers. They can be identified by routine screening tests used by laboratories such as Gentronix.

There are also non-genotoxic carcinogens that alter patterns of gene expression without changing the number or sequence of chromosomes.

There are currently no widely used screening tests available for these and they might only be identified in later animal exposure studies, which are time consuming, costly and come quite late in product development - an expensive time to fail.

Epigenetics is a relatively new field, concerned with the regulation of genes by chromosome modifications which don’t change the DNA sequence or chromosome numbers.

Epigenetic changes can also lead to the development of cancers and it is this aspect of early toxicology screening that the team at Gentronix Ltd., led by Chief Scientist, Prof. Richard Walmsley will be looking to address under the award.

Gentronix CEO, John Nicholson said “Gentronix has an excellent track record of innovation, and though as a growing company we have to balance innovative research with customer priorities, the award of this grant gives us the opportunity to carry out important fundamental research; the results of which will allow us to make informed decisions about the commercial potential of an epigenetics-based assay as well as making a contribution to the science of genetics”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Improved In Vitro Genotoxicity Testing to Reduce Animal Testing
In conjunction with the University of Manchester, Gentronix has been granted a research award of £133,024.
Thursday, August 10, 2006
Gentronix Secures R&D Award
The two-year grant will provide Gentronix with two scientists, cell culture facilities, and supporting laboratory instrumentation at its Manchester Incubator Core Technology Facility premises.
Tuesday, April 11, 2006
Scientific News
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
New Cancer Drug Target in Dual-Function Protein
Scientists at The Scripps Research Institute (TSRI) have identified a protein that launches cancer growth and appears to contribute to higher mortality in breast cancer patients.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Molecular Map Provides Clues To Zinc-Related Diseases
Mapping the molecular structure where medicine goes to work is a crucial step toward drug discovery against deadly diseases.
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
Genetic Research Can Significantly Improve Drug Development
With drug development costs topping $1.2bn (£850 million) to get a single treatment to the point it can be sold and used in the clinic, could genetic analysis save hundreds of millions of dollars?
New Method Opens Door to Development of Many New Medicines
Findings from TSRI reveal human proteins are better drug targets than previously thought.
Diagnosing Systemic Infections Quickly, Reliably
Team develop rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Blood Test That Detects Early Alzheimer’s Disease
A research team, led by Dr. Robert Nagele from Rowan University School of Osteopathic Medicine and Durin Technologies, Inc., has announced the development of a blood test that leverages the body’s immune response system to detect an early stage of Alzheimer’s disease – referred to as the mild cognitive impairment (MCI) stage – with unparalleled accuracy.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!